Drug Profile


Alternative Names: Kynac; Kynacyte; L-threo-Dihydrosphingosine; SPC 100270

Latest Information Update: 14 Mar 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Research Triangle Park Laboratories
  • Developer Eli Lilly; Research Triangle Park Laboratories
  • Class Chemosensitisers
  • Mechanism of Action Protein kinase C inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Atopic dermatitis; Cancer; Psoriasis

Most Recent Events

  • 27 Apr 2001 Sphinx Pharmaceuticals is now called Sphinx Laboratories
  • 16 Jun 1999 A preclinical study has been added to the Cancer pharmacodynamics section
  • 28 May 1997 Phase-II clinical trials for Cancer in USA (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top